Columbia, Missouri 65201

  • Insulin Resistance

Purpose:

To determine whether treatment with the ENaC inhibitor, amiloride, improves endothelial function and arterial stiffness in obese insulin resistant subjects in a randomized placebo-controlled trial examining pre and postmenopausal women and age-matched men.


Study summary:

Overweight/obese males, pre- and post-menopausal females with insulin resistance, 30-70 years of age will be recruited. Following screening, eligible men and women will be randomly assigned to either amiloride (max dose 5mg) or placebo in a double-blinded design manner. After randomization, subjects will be scheduled for an outpatient visit to the undergo baseline assessment of arterial stiffness (carotid femoral pulse wave velocity - cfPWV) and endothelial function (brachial popliteal artery flow mediated dilation). Subject assessment will be repeated at 12 weeks and at 24 weeks.


Criteria:

Inclusion Criteria: - 30 to 70 years of age at randomization - Body mass index (BMI) 25.1-50 kg/m2 or waist circumference > 88 cm (> 35 in) in women and >102 cm (>40 in) in men. 3, 4 - One other characteristic of metabolic syndrome (elevated triglycerides ≥150 mg/dl; HDL cholesterol <40 mg/dl in men and <50 mg/dl in women; blood pressure ≥130/85 mm Hg or treatment for hypertension; impaired fasting glucose (≥100 mg/dl)) or fasting insulin level >10 mU/L (correlates with insulin resistance). Exclusion Criteria: 1. History of type 1 or type 2 diabetes 2. Known cardiovascular events within the last 12 months (stroke, acute coronary event, revascularization, heart failure hospitalization). 3. History of uncontrolled thyroid disease, chronic liver disease (cirrhosis) or GFR <50 ml/min. 4. Use of potassium sparing medications (angiotensin II receptor blockers, angiotensin converting enzymes inhibitors or mineralocorticoid receptor blockers) or use of potassium supplements. 5. Active cancer 6. Excessive alcohol consumption (>14 drinks/week for men, >7 drinks/week for women) 7. Current tobacco use 8. Non controlled hypertension 9. Participation in regular exercise > 3 days/wk per week at a moderate or vigorous intensity 10. Pregnancy or lactation in women (or women not using contraceptives) 11. Women who plan to become pregnant during the duration of the trial 12. Chronic use of NSAIDs 13. Potassium level > 5.0 mqE/L at time of screening 14. Blood pressure at screening <110/70


NCT ID:

NCT03837626


Primary Contact:

Principal Investigator
Camila Manrique Acevedo, MD
University of Missouri-Columbia

Camila Manrique Acevedo, MD
Phone: 573-8820999
Email: manriquec@health.missouri.edu


Backup Contact:

N/A


Location Contact:

Columbia, Missouri 65201
United States

Camila Manrique
Phone: 573-882-2273
Email: manriquec@health.missouri.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: August 03, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.